Edan Instruments

Edan Instruments Stock-Based Compensation

The Stock-Based Compensation (SBC) of Edan Instruments (300206.SZ) as of Oct 27, 2026 is 7.29 M CNY. In the previous year, Stock-Based Compensation (SBC) was 1.82 M CNY — a change of 300.00% (higher).

Stock-Based Compensation

7.29 MCNY

YoY

300.00%

Last updated:

Stock-Based Compensation (SBC) of Edan Instruments is 2022 7.29 M CNY. Stock-Based Compensation (SBC) of Edan Instruments was 2021 1.82 M CNY. It decreases by 300.00% higher compared to the previous year.

The Edan Instruments Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2021
1.82 M CNY
Jan 1, 2022
7.29 M CNY
The Edan Instruments Stock-Based Compensation history
YEARStock-Based CompensationYoY
7.29 MCNY+300.00%
1.82 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Edan Instruments Stock analysis

What does Edan Instruments do? Edan Instruments, Inc. generates revenue through the design, manufacture, and sale of medical equipment, including maternity product series like doppler fetal heart beat monitors, ultrasonic doppler fetal heart beat monitors, fetal/maternal monitors, and maternity integrated diagnostic monitoring systems. The company also sells electrocardiograph series such as digital twelve-channel electrocardiographs, digital six-channel electrocardiographs, and electrocardiographic workstations, along with monitoring products like portable multi-variable monitors and central monitoring systems. Additionally, Edan offers spare parts and in vitro diagnostics products to support its equipment and medical services. The primary buyers of Edan's products are healthcare institutions, including hospitals and clinics, which purchase medical devices for diagnostic and monitoring purposes. These institutions rely on Edan's maternity, electrocardiograph, and monitoring systems to provide patient care. The company's in vitro diagnostics products are also sold to medical facilities for laboratory testing needs. Edan's product segments are defined by medical equipment categories: maternity, electrocardiograph, monitoring, and ultrasonic image systems. The spare parts and in vitro diagnostics businesses complement these segments by providing essential accessories and diagnostic tools. Revenue is derived from direct sales of these products to healthcare providers, with no mention of third-party distribution or additional services beyond the described offerings. Edan Instruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Edan Instruments stock

Stock-Based Compensation (SBC) of Edan Instruments is 7.29 M CNY in 2022.

Stock-Based Compensation (SBC) of Edan Instruments changed from 1.82 M CNY to 7.29 M CNY, representing a 300.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Edan Instruments since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Edan Instruments historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Edan Instruments

All Key Metrics — Edan Instruments